Pharmaceutical company Venus Remedies joins the AMR Industry Alliance

Pharmaceutical company Venus Remedies said on Monday it had joined the AMR Industry Alliance – a league of more than 100 world-renowned organizations – to develop solutions to combat the serious public health threat posed by antimicrobial resistance.

Welcoming Venus Remedies as a new member, Melissa Mitchell, Head of the Antimicrobial Resistance (AMR) Industry Alliance Secretariat, said, “We are delighted to have Venus Remedies join our ranks.”

“As an organization, they are leading by example and making commendable efforts to counter the threat of AMR by improving access to AMR-relevant medications in third world countries and encouraging the appropriate use of antibiotics, as well as good management activities.

“Leading life sciences companies, like Venus Remedies, are playing a vital role in AMR mitigation and continue to strengthen multi-stakeholder collaborations,” Mitchell said in the release.

AMR Industry Alliance is the largest private sector coalition working to combat antimicrobial resistance through a coordinated, multi-pronged response.

Since its creation in 2017, it has continuously contributed to sustainable solutions to combat antimicrobial resistance by creating a broad industrial dynamic and facilitating collaboration between the public and private sectors.

Members of the alliance include R&D-based pharmaceutical, generics, diagnostics and biotechnology companies, as well as industry associations.

In addition to promoting innovation to prevent, diagnose and treat drug-resistant infections, this global coalition controls the emergence of resistance through appropriate use, addresses barriers to patient access to appropriate drugs and advances responsible manufacturing.

It is an honor to collaborate with the global life sciences industry under the umbrella of the AMR Industry Alliance and to design sustainable solutions to RAM.

“I hope this association will amplify our existing efforts against AMR globally by shaping relevant AMR policies and plugging the leaks in the current landscape of antibiotic research and manufacturing with a focus on on access and appropriate use,” said Saransh Chaudhary, CEO of Venus Medicine. Research Center (VMRC), said.

Joining Venus Remedies’ AMR Industry Alliance, which has played a commendable role in ensuring proper manufacturing and access to antibiotics, is part of the company’s ongoing efforts to partner with other organizations in a determined fight against AMR globally, the statement said. noted.

Present in 80 countries, Venus Remedies has enabled the sustainable supply of quality-assured antibiotics to countries that did not have ready access to them, Chaudhary said.

“Venus Remedies is one of the very few R&D-based pharmaceutical companies in the world that has focused on AMR for over a decade now. Many of its superbug solutions and last-line generic antibiotics have helped millions of patients and prevented the spread of bacterial resistance. from species to species,” the company said.

(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor

Comments are closed.